Banque Transatlantique SA Sells 52,815 Shares of Boston Scientific Corporation $BSX

Key Points

• Banque Transatlantique SA reduced its stake in Boston Scientific Corporation by 8.1%, selling 52,815 shares during the 1st quarter, now holding 599,044 shares valued at approximately $55.8 million.
• Recent earnings show Boston Scientific reported $0.75 earnings per share, exceeding analysts' expectations, with revenue of $5.06 billion for the quarter, marking a 22.8% year-over-year increase.
• Several brokerages have recently issued positive ratings for Boston Scientific, with target prices increased by firms including Citigroup and Wells Fargo, indicating strong market confidence in the stock.

Banque Transatlantique SA reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,044 shares of the medical equipment provider's stock after selling 52,815 shares during the quarter. Boston Scientific makes up about 1.0% of Banque Transatlantique SA's holdings, making the stock its 17th biggest holding. Banque Transatlantique SA's holdings in Boston Scientific were worth $55,847,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. AQR Capital Management LLC boosted its holdings in shares of Boston Scientific by 26.7% during the 1st quarter. AQR Capital Management LLC now owns 1,155,829 shares of the medical equipment provider's stock valued at $114,427,000 after buying an additional 243,893 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of Boston Scientific by 5.5% during the 1st quarter. Advisors Asset Management Inc. now owns 35,833 shares of the medical equipment provider's stock valued at $3,615,000 after buying an additional 1,863 shares in the last quarter. AlTi Global Inc. boosted its holdings in shares of Boston Scientific by 11.6% during the 1st quarter. AlTi Global Inc. now owns 15,427 shares of the medical equipment provider's stock valued at $1,556,000 after buying an additional 1,600 shares in the last quarter. Ancora Advisors LLC boosted its holdings in shares of Boston Scientific by 14.2% during the 1st quarter. Ancora Advisors LLC now owns 3,622 shares of the medical equipment provider's stock valued at $365,000 after buying an additional 450 shares in the last quarter. Finally, Amundi boosted its stake in Boston Scientific by 2.6% in the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock worth $1,212,408,000 after purchasing an additional 311,034 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BSX shares. Leerink Partners assumed coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $118.00 to $125.00 in a research report on Monday. Wells Fargo & Company raised their price target on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $117.79.

Insider Transactions at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,802,597.06. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 over the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.95 during trading hours on Monday, hitting $108.17. 3,811,236 shares of the company's stock were exchanged, compared to its average volume of 7,442,347. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $160.28 billion, a P/E ratio of 64.38, a P/E/G ratio of 2.58 and a beta of 0.65. The firm has a 50 day moving average of $104.77 and a two-hundred day moving average of $102.15. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the business earned $0.62 earnings per share. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.